Seeking Alpha

Basilea Pharmaceutica AG (BPMUF)

- Grey Market
  • Jun. 12, 2012, 8:19 AM
    (GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch.
    | Comment!
Visit Seeking Alpha's
BPMUF vs. ETF Alternatives
Company Description
Currently, there's no company description for BPMUF.